Low value of detection of KRAS2 mutations in circulating DNA to differentiate chronic pancreatitis to pancreatic cancer

We read with great interest the article by Maire et al (2002), who evaluate the K-Ras mutations in circulating DNA to differentiate pancreatic cancer from chronic pancreatitis. Based on this, we also analysed KRAS2 mutations in the serum of 30 patients with pancreatic cancer and 40 patients with chronic pancreatitis. Pancreatic cancer patients were staged by means of dynamic computed tomography, magnetic resonance imaging, and angiography and/or endoscopic ultrasonography. Diagnosis was histologically confirmed for the patients who underwent surgery. The diagnosis of chronic pancreatitis was based on the radiologic data obtained by means of either endoscopic retrograde cholangiopancreatography or computed tomography. DNA was extracted from 20 ml of the serum by using the QIAmp Blood Kit (Qiagen) and the mutations in codon 12 of the K-ras gene were searched as described previously (Jiang et al, 1989). As positive controls, we used DNA from neoplastic tissues of 10 patients with pancreatic carcinoma by using the DNeasy Tissue Kit (Qiagen). For molecular analysis, DNA was amplified in the codon 12 region introducing a restriction site (GACCT) for digestion with BstNl restriction enzyme (PCR-RFLP). DNA from peripheral blood resulted not mutated in the 40 patients with chronic pancreatitis and in the 30 with pancreatic carcinoma, while DNA from pancreatic neoplastic tissue resulted mutated in 70% of the samples. To verify our results, all the samples were analysed by direct sequencing using Big Dye terminator v 1.1 cycle sequencing Kit and performing runs on ABI Prism 310 genetic analyzer (Applied Biosystem) Despite what was mentioned in Maire's article, we failed to find any mutations in all patients analysed, as well as we failed to correlate K-ras mutations with the levels of tumour markers such as Ca 19.9, CA242, CA50, CEA. The results of the present investigation lead us to these conclusions: (1) the eventual presence of cancer cells in peripheral blood may be a rare event, even if numerous reports support the detection of K-ras abnormalities in the serum, (2) neoplastic cells are supposed to circulate in clusters, and consequently their cognition could be hampered by a single blood sample extraction. (3) Large amounts of nonmutated DNA, coming from leucocytes held in the buffy coat layer, might also mask some vestiges of the mutant type of K-ras gene

L’ESPRESSIONE DI HIPK2, REGOLATORE DELL’ATTIVITÀ DI P53, È RIDOTTA NEI TUMORI PANCREATICI.

VII Congresso AFaR, BENEVENTO. ABSTRACT BOOK C46

ANALISI DELLA PERDITA DI ETEROZIGOSI NELLA REGIONE 7q32-34 IN CAMPIONI ISTOLOGICI DI TUMORI PANCREATICI E PANCREATITI CRONICHE ISOLATI MEDIANTI LCM

Presentazione Orale. Abstract # C127. Ospedale San Giuseppe, Milan

Mitotane increases the radiotheraphy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines

Mitotane, 1,1-dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane (o,p'-DDD) is an agent with adrenotoxic effect, which is able to block cortisol synthesis. This drug and radiotherapy are used also in adrenal cancer treatment even if their biological action in this neoplasia remains unknown. We investigated the effects of o,p'-DDD and ionizing radiations (IR) on cell growth inhibition and cell cycle perturbation in H295R and SW13 adrenocortical cancer cells. Both cell lines were irradiated at a 6 Gy dose and were treated with o,p'-DDD 10(-5) M separately and with IR/o,p'-DDD in combination. This combination treatment induced an irreversible inhibition of cell growth in both adrenocortical cancer cells. Cell cycle analysis showed that IR alone and IR/o,p'-DDD in combination induced the cell accumulation in the G2 phase. At 120 h after IR, the cells were able to recover the IR-induced G2 block while cells treated with IR/o,p'-DDD were still arrested in G2 phase. In order to study the molecular mechanism involved in the G2 irreversible arrest, we have considered the H295R cell line showing the highest inhibition of cell proliferation associated with a noteworthy G2 arrest. In these cells, cyclin B1 and Cdk2 proteins were examined by western blot and Cdk2 kinase activity measured by assay kit. The H295R cells treated with IR/o,p'-DDD shared an increase in cyclin B1 amount as the coimmunoprecipitation of Cdc2-cyclin B1 complex. The kinase activity also shows an increase in the treated cells with combination therapy. Moreover, in these cells, sequence analysis of p53 revealed a large deletion of exons 8 and 9. The same irreversible block on G2 phase, induced by IR/o,p'-DDD treatment, happened in H295R cells with restored wild-type p53 suggesting that this mechanism is not mediated by p53 pathway